Author

Etsuya Bando

Institution: Bristol-Myers Squibb (Japan)

Observed institution: Bristol-Myers Squibb (Japan)

OpenAlex ID: A5034016183

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan

2018 · Fumitaka Suzuki, Naoya Hatanaka, et al. · Hepatology International · 10

Correction: Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

2025 · Tomo Nozawa, Naomi Iwata, et al. · Pediatric Rheumatology · 2

Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

2025 · Tomo Nozawa, Naomi Iwata, et al. · Pediatric Rheumatology · 2

O-094 : Post Marketing Surveillance of Daclatasvir/Asunaprevir in Japanese Patients with Chronic Hepatitis C: An Interim Report

2017 · Fumitaka Suzuki, Naoya Hatanaka, et al. · 춘·추계 학술대회 (KASL)

Works count: 4

Citation count: 14

H-index: 2

I10-index: 1